1359404
USP
Levetiracetam
United States Pharmacopeia (USP) Reference Standard
Synonym(s):
(αS)-α-Ethyl-2-oxo-1-pyrrolidineacetamide, 2(S)-(2-Oxopyrrolidin-1-yl)butyramide
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C8H14N2O2
CAS Number:
Molecular Weight:
170.21
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
Recommended Products
grade
pharmaceutical primary standard
API family
levetiracetam
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CC[C@H](N1CCCC1=O)C(N)=O
InChI
1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
InChI key
HPHUVLMMVZITSG-LURJTMIESA-N
Gene Information
human ... CACNA1B(774) , SV2A(9900)
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Levetiracetam USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Biochem/physiol Actions
Levetiracetam is a pyrrolidine with antiepileptic activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Related product
Product No.
Description
Pricing
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Gashirai K Mbizvo et al.
The Cochrane database of systematic reviews, 9(9), CD001901-CD001901 (2012-09-14)
Epilepsy is an important neurological condition and drug resistance in epilepsy is particularly common in individuals with focal seizures. In this review, we summarise the current evidence regarding a new antiepileptic drug, levetiracetam, when used as add-on treatment for controlling
Benjamin W Y Lo et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 38(3), 475-486 (2011-04-26)
New evidence suggests that levetiracetam may be as effective as traditional agents, with better safety profile. To synthesize evidence regarding efficacy and tolerability of levetiracetam as first line, adjunctive or prophylactic antiepileptic agent. Study Selection & Data Extraction: Eligible studies
Brian Longo et al.
The Annals of pharmacotherapy, 43(10), 1692-1695 (2009-08-20)
To review data evaluating levetiracetam management of epilepsy during pregnancy. A literature search of PubMed (1966-June 2009) was performed using the terms pregnancy, epilepsy, levetiracetam, and anticonvulsants. Bibliographies of all articles retrieved were reviewed to identify additional relevant articles. All
Amy Z Crepeau et al.
Expert review of neurotherapeutics, 10(2), 159-171 (2010-02-09)
Levetiracetam was approved by the US FDA in 1999 after failing the traditional screening tests for antiepileptic drugs. In the 10 years since its introduction, it has become one of the first-line antiepileptic agents and has been evaluated in small
Vincenzo Belcastro et al.
Brain & development, 33(4), 289-293 (2010-07-16)
Several new antiepileptic drugs (AEDs) have been introduced for clinical use recently. These new AEDs, like the classic AEDs, target multiple cellular sites both pre- and postsynaptically. The use of AEDs as a possible neuroprotective strategy in brain ischemia is
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service